Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Safety Study of Adjunctive Troriluzole in OCD
2020-004654-30Phase 3Active
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of troriluzole in obsessive compulsive disorder (OCD) and anxiety disorder, sponsored by Biohaven Ltd. Primary endpoint: Long-term safety and tolerability of troriluzole. Started Jul 2021; status: active.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)anxiety disorder
Beyond the preview
Go deeper on 2020-004654-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004654-30.